Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

J Mulvey J, Magro C, Chadburn A. Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy. Blood Cells Mol Dis. 2018;69:38-42.

Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, et al. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol. 2018;31(5):791-808.

Saab J, Santos-Zabala ML, Loda M, Stack EC, Hollmann TJ. Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi. Am J Dermatopathol. 2018;40(4):259-264.

Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP, et al. High -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018;131(25):2816-2825.

Hata T, Suenaga M, Marchionni L, Macgregor-Das A, Yu J, Shindo K, et al. Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. Am J Pathol. 2018;188(7):1723-1733.

Hsu JM, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, et al. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018;24(2):359-365.

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, et al. Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res. 2018;78(10):2747-2759.

Haas T, Cushing MM, Asmis LM. Comparison of the efficacy of two human fibrinogen concentrates to treat dilutional coagulopathy in vitro. Scand J Clin Lab Invest. 2018;78(3):230-235.

Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, et al. Publisher Correction: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;563(7731):E24.

Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. J Hematol Oncol. 2018;11(1):105.